The global pharmaceutical industry had to wait a while for its next blockbuster drug which came in the form of semaglutide, originally meant to treat diabetes but eventually found to be aiding weight loss. It is indeed turning out to be a wonder drug with new studies now showing anti-ageing benefits. Intuitively reducing weight should reduce the risk of other life threatening diseases such as cardiovascular among others and hence in turn extend life expectancy and slow down ageing. But the studies seem to suggest the drug can be a health promoter.
“Weight-loss drugs are poised to revolutionise healthcare by slowing down the ageing process and by allowing people to live for longer and in better health. That is the dramatic message from leading scientists after studies were presented last week at the European Society of Cardiology Conference in London.
Research has already found that semaglutide – also known by the brand names Wegovy and Ozempic – reduced the risk of death in people who were obese or overweight and had cardiovascular disease.
But fresh studies have found that Ozempic has impacts beyond what was originally imagined for the drug. People who took the drug died at a lower rate from all causes, not just from cardiovascular causes, researchers discovered.
“Semaglutide has far-reaching benefits beyond what we initially imagined,” said Prof Harlan Krumholz of the Yale school of medicine. “It’s not just avoiding heart attacks. These are health promoters. It wouldn’t surprise me that improving people’s health this way actually slows down the ageing process.”
The studies were produced from the Select trial in the US, which studied 17,604 people aged 45 or older who were overweight or obese and had established cardiovascular disease but not diabetes. They received semaglutide or a placebo and were tracked for more than three years.
A total of 833 participants died during the study, of which 58% were related to cardiovascular causes and 42% from others, with infections being the most common cause of death in this latter group. Crucially, those who took semaglutide were less likely to die of infections than those in the placebo group while it also consistently reduced the risk of adverse cardiovascular outcomes, it was found.”
If you want to read our other published material, please visit https://marcellus.in/blog/
Note: The above material is neither investment research, nor financial advice. Marcellus does not seek payment for or business from this publication in any shape or form. The information provided is intended for educational purposes only. Marcellus Investment Managers is regulated by the Securities and Exchange Board of India (SEBI) and is also an FME (Non-Retail) with the International Financial Services Centres Authority (IFSCA) as a provider of Portfolio Management Services. Additionally, Marcellus is also registered with US Securities and Exchange Commission (“US SEC”) as an Investment Advisor.
